Sandoz Group AG SANDOZ GROUP ORD .../ CH1243598427 /
2024-05-24 5:19:23 PM | Chg. - | Volume | Bid6:00:05 AM | Ask6:00:05 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
32.17CHF | - | 80,833 Turnover: 699,394.51 |
-Bid Size: - | -Ask Size: - | 14.18 bill.CHF | - | - |
GlobeNewswire
05-22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
05-13
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04-30
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
04-30
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
04-22
Samsung Bioepis Gains European Commission Approval For PYZCHIVA™, a Biosimilar to Stelara (Ustekinum...
GlobeNewswire
04-22
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
03-21
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
03-09
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of ...
GlobeNewswire
03-04
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
02-29
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
02-13
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire
01-31
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
01-22
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All ...
GlobeNewswire
01-22
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
2023-11-30
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara®